BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Pharmacogenetics
,
Trichostatin A
,
rs2476601
,
FABP1
,
calcium channel activity
,
Heart
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
BTNL9;jsessionid=6A701016019599AB5EC8D51E96D5417B
(gene)
Summary
General Info
Body Atlas
Most Correlated Tissues
Omental adipose tissue
Lung
Adipose tissue subcutaneous
Heart ventricle
Adipose tissue
Explore Body Atlas Results
Disease Atlas
Most Correlated Diseases
Loading...
Explore Disease Atlas Results
Pharmaco Atlas
Most Correlated Compounds
Loading...
Explore Pharmaco Atlas Results
Knockdown Atlas
Most Correlated Gene Perturbations
Loading...
Explore Knockdown Atlas Results
Curated Studies
Most Correlated Studies
Loading...
Explore Curated Studies Results
Literature
Most Relevant Literature
A stop-gain variant in BTNL9 is associated with atherogenic lipid profiles.
Butyrophilin-like 9 expression is associated with outcome in lung adenocarcinoma.
Structure-Activity Relationships of Butyrophilin 3 Ligands.
Integrative omics analysis identifies biomarkers of idiopathic pulmonary fibrosis.
Potent Bidirectional Cross-Talk Between Plasmacytoid Dendritic Cells and γδT Cells Through BTN3A, Ty…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
There were no clinical trials for BTNL9;jsessionid=6A701016019599AB5EC8D51E96D5417B
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ